PD-L1 on Host Cells is Essential for PD-L1 Blockade–mediated Tumor Regression
Haidong Tang,Yong Liang,Robert A. Anders,Janis M. Taube,Xiangyan Qiu,Aditi Mulgaonkar,Xin Liu,Susan M. Harrington,Jingya Guo,Yangchun Xin,Yahong Xiong,Kien Nham,William Silvers,Guiyang Hao,Xiankai Sun,Mingyi Chen,Raquibul Hannan,Jian Qiao,Haidong Dong,Hua Peng,Yang-Xin Fu
DOI: https://doi.org/10.1172/jci96061
IF: 19.456
2018-01-01
Journal of Clinical Investigation
Abstract:Programmed death-ligand 1 (PD-L1) expression on tumor cells is essential for T cell impairment, and PD-L1 blockade therapy has shown unprecedented durable responses in several clinical studies. Although higher expression of PD-L1 on tumor cells is associated with a better immune response after Ab blockade, some PD-L1-negative patients also respond to this therapy. In the current study, we explored whether PD-L1 on tumor or host cells was essential for anti-PD-L1-mediated therapy in 2 different murine tumor models. Using real-time imaging in whole tumor tissues, we found that anti-PD-L1 Ab accumulates in tumor tissues, regardless of the status of PD-L1 expression on tumor cells. We further observed that, while PD-L1 on tumor cells was largely dispensable for the response to checkpoint blockade, PD-L1 in host myeloid cells was essential for this response. Additionally, PD-L1 signaling in defined antigen-presenting cells (APCs) negatively regulated and inhibited T cell activation. PD-L1 blockade inside tumors was not sufficient to mediate regression, as limiting T cell trafficking reduced the efficacy of the blockade. Together, these findings demonstrate that PD-L1 expressed in APCs, rather than on tumor cells, plays an essential role in checkpoint blockade therapy, providing an insight into the mechanisms of this therapy.